Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
A pilot study was undertaken to assess the safety, activity, and immunogenicity of a polyvalent Wilms tumor gene 1 (WT1) peptide vaccine in patients with acute myeloid leukemia in complete remission but with molecular evidence of WT1 transcript. Patients received 6 vaccinations with 4 WT1 peptides (200 μg each) plus immune adjuvants over 12 weeks. Immune responses were evaluated by delayed-type hypersensitivity, CD4+ T-cell proliferation, CD3+ T-cell interferon-γ release, and WT1 peptide tetramer staining. Of the 9 evaluable patients, 7 completed 6 vaccinations and WT1-specific T-cell responses were noted in 7 of 8 patients. Three patients who were HLA-A0201-positive showed significant increase in interferon-γ–secreting cells and frequency of WT1 tetramer-positive CD8+ T cells. Three patients developed a delayed hypersensitivity reaction after vaccination. Definite related toxicities were minimal. With a mean follow-up of 30 plus or minus 8 months after diagnosis, median disease-free survival has not been reached. These preliminary data suggest that this polyvalent WT1 peptide vaccine can be administered safely to patients with a resulting immune response. Further studies are needed to establish the role of vaccination as viable postremission therapy for acute myeloid leukemia. This study was registered at www.clinicaltrials.gov as #NCT00398138.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Central Role of CD4+ T Cells in the Antitumor Immune Response
Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., & Levitsky, H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2357 · Cited by 1,345
Cited by
Gaur, M., Misra, C., Yadav, A. B., Swaroop, S., Maolmhuaidh, F. Ó., Bechelany, M., & Barhoum, A. (2021) · Materials · doi:10.3390/ma14205978 · Cited by 317
Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene
Huff, V. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3002 · Cited by 266
Anguille, S., Van de Velde, A. L., Smits, E. L., Van Tendeloo, V. F., Juliusson, G., Cools, N., Nijs, G., Stein, B., Lion, E., Van Driessche, A., et al. (2017) · Blood · doi:10.1182/blood-2017-04-780155 · Cited by 230
Next-generation peptide vaccines for advanced cancer
Yamada, A., Sasada, T., Noguchi, M., & Itoh, K. (2013) · Cancer Science · doi:10.1111/cas.12050 · Cited by 124
Haematological malignancies: at the forefront of immunotherapeutic innovation
Bachireddy, P., Burkhardt, U. E., Rajasagi, M., & Wu, C. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3907 · Cited by 85
Metadata
- Authors
- Maslak, P. G., Dao, T., Krug, L. M., Chanel, S., Korontsvit, T., Zakhaleva, V., Zhang, R., Wolchok, J. D., Yuan, J., Pinilla-Ibarz, J., Berman, E., Weiss, M., Jurcic, J., Frattini, M. G., & Scheinberg, D. A.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2010-07-15
- Volume
- 116
- Issue
- 2
- Pages
- 171-179
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2148301776
- Cited by
- 154
- References
- 1
- FWCI
- 5.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. https://app.cochat.ai/papers/10.1182/blood-2009-10-250993
- The paper
- Maslak, P. G., Dao, T., Krug, L. M., Chanel, S., Korontsvit, T., Zakhaleva, V., Zhang, R., Wolchok, J. D., Yuan, J., Pinilla-Ibarz, J., Berman, E., Weiss, M., Jurcic, J., Frattini, M. G., & Scheinberg, D. A. (2010). Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood. https://doi.org/10.1182/blood-2009-10-250993
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.